The in vitro study of the susceptibility of Bifidobacteria to antidepressants
This in vitro study demonstrates that the serotonin modulator and stimulator Brintellix (vortioxetine) exhibits significantly stronger antimicrobial activity against 22 strains of Bifidobacterium compared to the SSRIs Cipralex and Seropram, suggesting that antidepressant class influences their impact on gut microbiota.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine your body as a bustling, microscopic city. Inside your gut, this city is teeming with trillions of tiny residents called bacteria. Some of these residents are the "good guys," like the Bifidobacterium family, who act like friendly neighborhood gardeners. They help digest food, keep the gut walls strong, and even send little chemical messages up to your brain that can help you feel calm and happy. This connection between your gut garden and your brain is often called the "gut-brain axis."
Now, imagine that millions of people around the world are feeling so sad or stuck that they need help from special medicines called antidepressants. These drugs are like powerful traffic controllers for the brain, helping to smooth out the flow of happy chemicals so people can function better. But here's the big question: when these medicines travel through the body to reach the brain, do they accidentally bump into or hurt the friendly gardeners in the gut? Scientists have known for a while that these drugs can change the gut city, but they didn't know exactly how different types of these medicines treated the good bacteria. It's like wondering if a new type of rain would help the flowers grow or wash them away.
This is where a team of researchers from the Czech Academy of Science and the National Institute of Mental Health stepped in. They wanted to play a game of "who gets the most wet" with 22 different strains of friendly Bifidobacterium bacteria and three popular antidepressant medicines. They didn't use real people; instead, they grew the bacteria in test tubes (a lab setting called in vitro) and added the medicines to see what happened. The three medicines they tested were Brintellix (vortioxetine), Cipralex (escitalopram), and Seropram (citalopram). While Cipralex and Seropram are the classic "SSRI" type of traffic controllers, Brintellix is a newer, slightly different kind called an "SMS" (serotonin modulator and stimulator).
The scientists mixed the bacteria with the medicines at three different strengths: 200, 400, and 600 micrograms per milliliter (µg/mL). Think of these as light, medium, and heavy doses. They then watched the bacteria grow over 24 hours, measuring how much the liquid in the test tubes got cloudy (which means the bacteria were multiplying).
Here is what they found, and it's a bit of a surprise. The medicines didn't treat all the bacteria the same way, and they didn't treat all the bacteria the same way as each other.
First, Brintellix turned out to be the toughest on the bacteria. It acted like a heavy storm that slowed down almost every single strain of Bifidobacterium. In fact, at the highest dose (600 µg/mL), it stopped the growth of all 22 strains, though one specific strain (B. longum subsp. infantis) was able to resist the lowest dose of 200 µg/mL. On average, it reduced their growth by about 73% at the highest dose. The researchers calculated a number called the "IC₅₀" (which is the amount of drug needed to stop half the bacteria from growing), and Brintellix had the lowest number, meaning it was the most powerful at holding the bacteria back.
Cipralex was more like a gentle drizzle. It slowed down some of the bacteria, but many of them kept growing just fine. It had a moderate effect, reducing growth by about 58% at the highest dose, but it didn't stop as many strains as Brintellix did.
Seropram was the weakest of the three, acting more like a light mist. It had the least impact on the bacteria, with some strains growing almost as if the medicine wasn't even there. At the highest dose, it reduced growth by about 58%, but it took a lot more of it to get that result compared to Brintellix.
The researchers also noticed that some specific bacteria were tough cookies. For example, a few strains of B. bifidum and B. dentium were completely resistant to Seropram and Cipralex, meaning those medicines didn't slow them down at all. However, no strain was completely immune to Brintellix; even the toughest bacteria slowed down when hit with that drug.
So, what does this mean? The study suggests that not all antidepressants are created equal when it comes to the gut. The newer drug, Brintellix, seems to have a much stronger "antibacterial" effect on these friendly gut bacteria than the older SSRIs like Cipralex and Seropram. The authors are careful to say this is just a first look in a test tube, not a final answer for what happens inside a real human body. They point out that in a real person, the drug gets diluted and absorbed in different ways, so the actual amount hitting the bacteria might be different.
However, the findings are a big clue. It suggests that if a doctor is choosing a medicine for a patient who also needs to protect their gut health, or if someone is taking probiotics to help with depression, the type of antidepressant matters. The study hints that the newer "SMS" class of drugs might shake up the gut garden more than the traditional ones. The researchers conclude that we need more studies to see how this plays out in real life, but for now, we know that these medicines are not just invisible to our gut bacteria; they interact with them, and sometimes, that interaction is quite strong.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.